NCT07098585View on ClinicalTrials.gov

To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

June 6, 2025

Study Completion Date

July 17, 2025

Conditions

Attention Deficit/Hyperactivity Disorder (ADHD)

Interventions

DRUG

Lisdexamfetamine capsule

Lisdexamfetamine 70 mg capsule

DRUG

Elvanse® (Lisdexamfetamine dimesylate capsules, hard)

Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard)

Trial Locations (1)

380 051

Cliantha Research Limited, Ahmedabad

All Listed Sponsors

lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT07098585 - To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions. | Biotech Hunter | Biotech Hunter